Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRAF/MEK targeted therapy. In total, 192 patients wer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2021-02, Vol.27 (2), p.301-309
Hauptverfasser:	Menzies, Alexander M., Amaria, Rodabe N., Rozeman, Elisa A., Huang, Alexander C., Tetzlaff, Michael T., van de Wiel, Bart A., Lo, Serigne, Tarhini, Ahmad A., Burton, Elizabeth M., Pennington, Thomas E., Saw, Robyn P. M., Xu, Xiaowei, Karakousis, Giorgos C., Ascierto, Paolo A., Spillane, Andrew J., van Akkooi, Alexander C. J., Davies, Michael A., Mitchell, Tara C., Tawbi, Hussein A., Scolyer, Richard A., Wargo, Jennifer A., Blank, Christian U., Long, Georgina V.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1813/1634 692/308/53/2422 Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biomedical and Life Sciences Biomedicine Cancer Research Clinical trials Consortia Disease-Free Survival Drug therapy Female Humans Immunotherapy Immunotherapy - adverse effects Infectious Diseases Ipilimumab - administration & dosage Ipilimumab - adverse effects Male Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - immunology Melanoma - pathology Metabolic Diseases Middle Aged Molecular Medicine Molecular Targeted Therapy Monoclonal antibodies Neoadjuvant therapy Neoadjuvant Therapy - adverse effects Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - immunology Neoplasm Recurrence, Local - pathology Neurosciences Nivolumab - administration & dosage Nivolumab - adverse effects Patient outcomes Patients PD-1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - genetics Proto-Oncogene Proteins B-raf - genetics Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - immunology Skin Neoplasms - pathology Survival Therapy Toxicity Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!